Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
← catalyst calendarSponsored by Celltrion (industry) · 068270.KS — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
606actual
Sites
1
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-27 | actual | When the study began enrolling |
| Primary completion | 2026-04-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-04 | actual | The whole study's end, after follow-up |
| First posted | 2024-08-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- T2DM
Interventions
- Drug: CT-L03 Group 1
- Drug: CT-L03 Group 2
- Drug: Placebo
- Drug: Empagliflozin
- Drug: Metformin
Primary outcome
what the primary-completion date above is the date OFHbA1c
measured Week 24 of the Treatment
Permalink · 068270.KS's whole pipeline · Catalyst calendar · Every registered study · What changed